Möchten Sie immer auf dem neuesten Stand bleiben?

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of...

Belleville, Illinois, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Allsup, a leading provider of Social Security Disability Insurance (SSDI) representation, return to work and veterans disability appeals...

HORGEN, Switzerland and TOKYO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology...

Yaqrit progresses novel treatment into pilot study for primary sclerosing cholangitis and IBD. Results expected H2 2026

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely...

Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract...

EXTON, PA, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Patients with inflammatory bowel disease (IBD) in the US are taking a more active role than ever before in the decision to switch their advanced...

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative...

Pasithea adds ETS2 expert Dr. James Lee to its SAB to guide PAS-004 development for IBD and other inflammatory diseases driven by ETS2.

Pasithea’s PAS-004 shows superior ETS2 inhibition vs. selumetinib, highlighting promise as a new treatment for IBD and other inflammatory diseases.